H. N. OLGUN Et Al. , "Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience," Frontiers in Oncology , vol.12, 2022
OLGUN, H. N. Et Al. 2022. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience. Frontiers in Oncology , vol.12 .
OLGUN, H. N., ÇEÇEN, R. E., İNCE, D., KIZMAZOĞLU, D., BAYSAL, B., Onal, A., ... ÖZDOĞAN, Ö.(2022). Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience. Frontiers in Oncology , vol.12.
OLGUN, HATİCE Et Al. "Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience," Frontiers in Oncology , vol.12, 2022
OLGUN, HATİCE N. Et Al. "Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience." Frontiers in Oncology , vol.12, 2022
OLGUN, H. N. Et Al. (2022) . "Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience." Frontiers in Oncology , vol.12.
@article{article, author={HATİCE NUR OLGUN Et Al. }, title={Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience}, journal={Frontiers in Oncology}, year=2022}